Rankings
▼
Calendar
AQST Q4 2025 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AQST
Aquestive Therapeutics, Inc.
$431M
Q4 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$13M
+9.7% YoY
Gross Profit
-$34M
-264.2% margin
Operating Income
-$29M
-221.6% margin
Net Income
-$32M
-244.8% margin
EPS (Diluted)
$-0.24
QoQ Revenue Growth
+1.6%
Cash Flow
Operating Cash Flow
-$8M
Free Cash Flow
-$9M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$160M
Total Liabilities
$194M
Stockholders' Equity
-$34M
Cash & Equivalents
$121M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13M
$12M
+9.7%
Gross Profit
-$34M
$7M
-568.1%
Operating Income
-$29M
-$14M
-112.4%
Net Income
-$32M
-$17M
-86.8%
Revenue Segments
Manufacture and Supply Revenue
$12M
92%
License and Royalty Revenue
$852,000
7%
Co-Development and Research Fees
$181,000
1%
Geographic Segments
UNITED STATES
$9M
72%
Non-US
$4M
28%
← FY 2025
All Quarters